SCHEMBL9625161

SCHEMBL9625161

CCCc1occc(=O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
LMNA P02545 1/20 0.52
APP P05067 6/20 0.36
MAPK1 P28482 1/20 0.34
FTO Q9C0B1 1/20 0.34
CYP2C9 P11712 2/20 0.33
MMP1 P03956 1/20 0.33
MMP3 P08254 1/20 0.33
MMP7 P09237 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP12 P39900 1/20 0.33
MMP13 P45452 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
PRKCI P41743 1/20 0.33
POLB P06746 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HSD17B3 P37058 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9625506 0.89 KDM4E (0.48) KDM4ELMNAAPPALDH1A1HPGD
SCHEMBL10902501 0.87 KDM4E (0.47) KDM4ELMNAALDH1A1HPGD
SCHEMBL11761929 0.86 KDM4E (0.46) KDM4ELMNAALDH1A1
SCHEMBL11759473 0.86 KDM4E (0.46) KDM4ELMNAALDH1A1
SCHEMBL11755938 0.86 KDM4E (0.46) KDM4ELMNAALDH1A1
SCHEMBL11760812 0.86 KDM4E (0.46) KDM4ELMNAALDH1A1
SCHEMBL10903156 0.86 KDM4E (0.46) KDM4ELMNAALDH1A1
E637 SCHEMBL1870685 0.84 KDM4E (0.55) KDM4ELMNAAPPMAPK1FTO
E637 SCHEMBL41817 0.84 KDM4E (0.55) KDM4ELMNAAPPMAPK1FTO
E637 SCHEMBL23309786 0.82 KDM4E (0.53) KDM4ELMNAAPPMAPK1FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US claimed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP claimed
CN-118660702-A Antimicrobial compositions 生物活性协同有限公司 2024-09-17 CN claimed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO claimed
EP-0473764-A1 METAL COMPLEXES Hider, Robert Charles (GB) 1992-03-11 EP claimed
WO-1991014664-A1 METAL COMPLEXES HIDER ROBERT CHARLES (GB) 1991-10-03 WO claimed
EP-0263138-B1 IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1991-06-12 EP claimed
US-4894455-A Pharmaceutically active zinc complexes NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1990-01-16 US claimed
US-4866052-A TREATING BLOOD WITH ZINC HYDROXY YRONE COMPLETE ENHANCES OXYGE N BINDING AFFINITY NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1989-09-12 US claimed
EP-0271529-A1 PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-06-22 EP claimed
EP-0263138-A1 IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE. NAT RES DEV (GB) 1988-04-13 EP claimed
WO-1987007893-A1 PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-12-30 WO claimed
WO-1987005509-A1 IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-09-24 WO claimed
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US disclosed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP disclosed
CN-118660702-A Antimicrobial compositions 生物活性协同有限公司 2024-09-17 CN disclosed
EP-0263138-A1 IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE. NAT RES DEV (GB) 1988-04-13 EP disclosed
WO-1987007893-A1 PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-12-30 WO disclosed
WO-1987005509-A1 IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-09-24 WO disclosed
US-4059595-A Process for preparing 3-oxy-4H-pyran-4-one derivatives OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHI (JA) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS NOD2, PYCARD, CLPP KDM4E 4332/4885LMNA 2204/4885APP 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.